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Abstract 
The reason why a sustained high concentration of insulin induces laminitis in horses 
remains unclear. Cell proliferation occurs in the lamellae during insulin-induced laminitis and 
high concentrations of insulin can activate receptors for the powerful cell mitogen, insulin-
like growth factor (IGF) -1 in other species. The first aim of this study was to determine if 
IGF-1 receptors (IGF-1R) are activated in the hoof during insulin-induced laminitis. Gene 
expression for IGF-1R and the insulin receptor (InsR) was measured using qRT-PCR, in 
lamellar tissue from control horses and from horses undergoing a prolonged euglycaemic, 
hyperinsulinaemic clamp (p-EHC), during the mid-developmental (24 h) and acute (46 h) 
phases of insulin-induced laminitis. Gene expression for both receptors was decreased 13 -32 
fold (P < 0.05) at both time-points in the insulin-treated horses.  
 
A second aim of the study was to determine if the down-regulation of the receptor 
genes could be accounted for by an increase in circulating IGF-1. Serum IGF-1 was measured 
at 0, 10, 25 and 46 h post-treatment in horses given a p-EHC for approximately 46 h, and in 
matched controls administered a balanced, electrolyte solution. There was no increase in 
serum IGF-1 concentrations during the p-EHC, consistent with down-regulation of both 
receptors by insulin. Stimulation of the IGF-1R by insulin may lead to inappropriate lamellar 
epidermal cell proliferation and lamellar weakening, a potential mechanism for 
hyperinsulinaemic laminitis. Targeting this receptor may provide insights into the 
pathogenesis or identify a novel therapy for hyperinsulinaemic laminitis. 
 
Keywords: Equine; Laminitis; Insulin; Insulin-like growth factor-1 receptor 
  
Introduction 
 There is strong evidence that hyperinsulinaemia is central to the development of 
endocrinopathic laminitis (McGowan et al., 2008a; Treiber et al., 2008), and this can be 
replicated experimentally using a prolonged-euglycaemic, hyperinsulinaemic clamp (p-EHC) 
technique (Asplin et al., 2007; de Laat et al., 2010). Recently, this model was used to 
investigate the mechanism of insulin-induced laminitis. The classical effects of insulin, such 
as alterations in glucose uptake/metabolism and changes in blood flow, known to occur at 
physiological concentrations could not be incriminated, leaving the pathogenesis of insulin-
induced laminitis speculative (Asplin et al., 2011; de Laat et al., 2011a,b; 2012b,c). 
 
Insulin-like growth factor (IGF) -1 is a polypeptide with close structural homology to 
insulin, with known effects in terms of activating cell proliferation and tissue growth and 
repair (Laviola et al., 2007). Although insulin and IGF-1 have many actions in common, such 
as the stimulation of glucose and amino acid uptake into tissues, they serve different roles in 
the body and their actions are controlled differently. Insulin has short-term effects on 
regulating blood glucose, and its action is governed in the healthy animal by tight control 
over the rate of insulin secretion from its only source, the pancreas. In contrast, IGF-1 is 
produced locally in small amounts by many tissues and in large amounts by the liver. IGF-1 
concentrations in the blood are comparatively stable and are typically much higher than those 
of insulin. However, more than 90% of the peptide is bound to a family of IGF-1-specific 
binding proteins which serve as a reservoir and a critical regulator of IGF-1 action (Madan et 
al., 2011).   
 
To produce their effects, insulin and IGF-1 bind with strong affinity to specific 
tyrosine kinase receptors on the cell surface (LeRoith and Yakar, 2007; Chitnis et al., 2008). 
Both receptor types are found on many cells, and IGF-1 receptors (IGF-1R) have been 
identified only recently in the lamellar epidermis of normal horses (Bailey and 
Chockalingham, 2009). In common with all ligands, insulin and IGF-1 have the highest 
binding affinity for their own receptors, and at normal physiological concentrations discreet 
actions can generally be ascribed to one peptide or the other. Nevertheless, ‘cross-talk’ 
between receptors has been reported and a hybrid insulin receptor (InsR) /IGF-1R is known 
to exist (Frattali et al., 1992). Furthermore, many hormones lose their specificity at high 
concentrations and significantly, insulin can activate the IGF-1R during conditions of 
hyperinsulinaemia (Ciaraldi and Sasaoka, 2010).  
 
The role of IGF-1R-mediated cell proliferation is of particular interest in the context 
of equine laminitis. We recently observed an increase in cell proliferation in the lamellae 
during the developmental stages of insulin-induced laminitis (de Laat et al., 2012a). 
Proliferation of lamellar epithelium is virtually non-existent in normal horses (Daradka and 
Pollitt, 2004), and if the proliferation of basal cells in the secondary epidermal lamellae 
(SEL) was stimulated excessively, this could potentially weaken the lamellar suspensory 
apparatus and thus potentially trigger the onset of clinical signs. 
 
An important part of investigating the role of the IGF-1R in insulin-induced laminitis 
is to demonstrate that IGF-1R activation occurs during the onset of the disease. The 
activation of specific growth-factor receptors in tissue can be difficult to demonstrate in vivo, 
but a classical response of chronically overstimulated receptors is to ameliorate their impact 
by increasing receptor breakdown and decreasing gene expression, so that fewer receptors are 
synthesised and available for activation (Komada and Kitamura, 2005; Madan et al., 2011).   
 
Thus, hyperinsulinaemia would be expected to result in a decrease in lamellar InsR 
gene expression during a p-EHC procedure in horses, and this would serve as a positive 
control supporting the contention that gene down-regulation follows excessive stimulation. A 
similar decrease in lamellar IGF-1R gene expression during a p-EHC would likewise suggest 
that the IGF-1R was excessively stimulated. The primary aim of the current study was to test 
the hypothesis that during a p-EHC, insulin decreases IGF-1R gene expression in horses.  
Plasma IGF-1 concentrations were also measured to support the proposition that any down-
regulation of IGF-1R gene expression was caused by insulin, and not by increased IGF-1 
secretion. 
Materials and methods 
Experimental ethics and procedure 
The experiment was approved by the Animal Ethics Committee of the University of 
Queensland (SVS/013/08/RIRDC and SVS/108/09/RIRDC) which ensured compliance with 
the Animal Welfare Act of Queensland (2001) and the Australian Code of Practice for the 
Care and Use of Animals for Scientific Purposes (NHMRC, 2004). Given that a key principle 
of this Code is to minimise the number of animals used in any particular experiment, 
consistent with measuring a statistically significant change in the variable of interest. The 
blood and tissue samples used in the current study were obtained from previous experiments 
where hyperinsulinaemia was induced in a small number of horses to achieve other objectives 
(de Laat et al., 2010; 2012a). As a result, although the number of horses/treatment group (4) 
was less than optimal for the present study, the numbers were sufficient to potentially 
generate statistically significant results. 
 
Twelve Standardbreds (11 geldings and 1 filly) were divided into three groups of four, 
with each group having a similar median bodyweight: group one weighed 440 (406 - 452) kg, 
with a median (range) age of 7.5 (3.5 - 11) years; group two averaged 451 (382 - 470) kg and 
were 6 (3.5 - 8) years old; and group three averaged 430 (414 - 453) kg and were 4.8 (4.2 - 6) 
years old. Groups one and two received a combined IV infusion of insulin at a fixed rate (6 
mIU/kg bodyweight/min; Humulin-R, Eli Lily), and glucose at a variable rate to maintain 
euglycaemia (50% dextrose, Baxter). The infusions were given for either 24 h (group 1), or 
until the onset of Obel (Obel, 1948) grade 2 laminitis (group 2) which occurred after 46 ± 2.3 
h (mean ± se). Each horse in group two was paired (by bodyweight) with a horse that 
received a balanced electrolyte solution at 0.57 mL/kg bodyweight/h (Hartmanns, Baxter) for 
the same period and these animals served as controls. 
 
At the end of each infusion the horses were euthanased with IV pentobarbital sodium 
(120 mL; Lethabarb, Virbac) and lamellar tissue was collected immediately from the left 
forefeet, snap frozen in liquid nitrogen and stored at -80 °C until analysed. Blood samples (10  
mL) were taken from the left jugular vein at 5 h intervals throughout the experiment to 
measure glucose and insulin concentrations. IGF-1 was measured every 10 h in groups two 
and three only.  
 
Measurement of glucose, insulin and insulin-like growth factor-1 
Glucose was measured immediately in whole blood with a hand-held glucometer 
(Accucheck-Go, Roche) which had been validated for use in horses against a hexokinase 
method (concordance, ρc = 0.96). Insulin and IGF-1concentrations were measured in serum 
stored at -80 °C. Insulin was measured with a radioimmunoassay (Coat-a-count, Siemens 
Healthcare Diagnostics) validated previously for use in the horse (McGowan et al., 2008b).  
Total IGF-1 concentrations were measured using a human ELISA kit after preliminary 
validation to determine its suitability for use with equine serum (Immunodiagnostic Systems).  
When used in accordance with the manufacturer’s instructions, the IGF-1 assay showed good 
parallelism over a range of serum dilutions. Interference from IGF-binding proteins is the 
principle cause of assay failure when human kits are used to measure equine IGF-1, and this 
typically leads to low values for IGF-1 recovery (Noble and Sillence, 2001b).  
 
In the present study, the recovery of IGF-1 was measured in three different equine 
samples that had been spiked in duplicate with recombinant human IGF-1 standard and 
allowed to incubate overnight at 4 oC. The mean recovery was 98.5%, indicating that no 
significant binding protein interference occurred. The intra-assay CV, determined using six 
replicates, was relatively high at 13.4%, but was still considered acceptable. Only one assay 
was performed in equine serum, but the inter-assay CV for this kit in human serum is 
reported by the manufacturer to be between 4.3 and 6.5%.  
 
RNA extraction and cDNA synthesis 
Frozen lamellar tissue (100 mg) was pulverised in a pre-chilled, heavy-duty foil 
envelope on a cold metal block. Total RNA was extracted according to the manufacturer’s 
instructions using 1 mL of Trizol reagent (Invitrogen). Each sample was visualised on a 2% 
agarose gel with SybrSafe stain (Invitrogen) to confirm RNA integrity, and the RNA 
concentration was determined by UV spectrophotometry. Prior to cDNA synthesis, RNA 
samples were treated with RNAse-free DNAse I (Invitrogen) to eliminate possible genomic 
DNA contamination. For each sample, 1 µg of total RNA was reverse-transcribed to cDNA 
using the Reverse Transcription System (Promega) and stored at -80 °C until analysed.  
 
Quantitative RT-PCR and PCR analyses 
SensiMix 2 x SYBR green Master Mix (Bioline) was used for qRT-PCR assays for 
relative quantification of InsR and IGF-1R in the tissue samples. Equine specific sequences 
for the target genes were not available on GenBank therefore the primer sets (Table 1) for the 
InsR were designed from the most conserved regions of human (HUMINSR), rat 
(RATINSAB) and mouse (MUSINSR) sequences, and cattle (X54980), rat (RATIGFIRT), 
pig (AB003362) and human (X04434) sequences were used in the case of IGF-1R. The PCR 
primer sets for two house-keeping genes (Table 1) were designed from equine-specific 
sequences (GenBank accession Nos: β2-microglobulin, X69083 and GAPDH, AF157626). 
Primers were designed using Primer3 v. 0.4.0 software and synthesised (Sigma Aldrich).  
 
As an ideal house-keeping gene for experimental laminitis has not been identified to 
date, two different genes were examined in order to allow selection of the more stable one. 
Amplification efficiency (E = 10[–1/slope]) of the target and house-keeping genes was analysed 
using serial dilutions of equine lamellar cDNA by qRT-PCR, with each primer set having 
efficiencies within 10% of two, which permits use of the 2-∆CT equation (Schmittgen and 
Livak, 2008). The specificity of all primers was checked via a BLAST search (Altschul et al., 
1997) and confirmed using 2% agarose gel electrophoresis. 
 
PCR reactions were set-up in 100-well genediscs (Qiagen) using a Corbett CAS-1200 
robot (Qiagen) and run on a Corbett Rotor-Gene 6000 series (Qiagen). The exact primer 
concentrations and PCR conditions were determined during initial optimisation runs.  
Following optimisation experiments, assays of 10 µL reaction volumes were prepared 
comprising 2 µL optimally diluted cDNA, 5 µL of SensiMix 2 x SYBR Green Master Mix 
(Bioline), 1 µL H20 and 2 µL of forward and reverse primers at varying concentrations as 
determined by optimisation experiments (Table 1). The cycling conditions were: 95 °C for 10 
min, followed by 45 cycles of 15 s at 95 °C, 15 s at 58 °C and 30 s at 72 °C.  The specificity 
of the amplified products was checked immediately after the PCR with melting curve 
analysis and sequencing of the PCR products. All samples were amplified on the same disc 
for every primer pair to ensure equal amplification conditions. No-template controls using 
water instead of cDNA templates were included for each gene as negative controls. Samples 
were amplified in duplicate and the results recorded as cycle threshold (CT) values of 
background-subtracted, qPCR fluorescence kinetics. For each sample, CT values for each 
target gene were averaged and relative gene expression was calculated for target genes 
against the reference gene, using the 2-∆CT method (Schmittgen and Livak, 2008). 
 
Statistical analyses 
 Given the small sample size, non-parametric analyses were used. Age, bodyweight, 
body condition score (BCS), blood glucose, serum insulin and gene expression results were 
compared among groups using a Kruskal-Wallis ANOVA on ranks. Serum IGF-1 data were 
compared within each group (at each time-point) with a Kruskal-Wallis ANOVA on ranks 
and between groups over the infusion period using Friedman’s repeated-measures ANOVA 
to examine for a potential interaction of group and time. Pair-wise comparisons were made 
with Tukey’s post-hoc test. All data are presented as median (inter-quartile range) and 
statistical significance was accepted at P < 0.05. Statistical analyses were performed using R, 
v. 7.2.7. 
Results 
Age, bodyweight, BCS and blood glucose concentration did not differ among groups. 
As expected, median (range) serum insulin concentrations (µIU/mL) were elevated (P < 0.05) 
in horses treated with a p-EHC for 24 h (918 [852 – 1123] µIU/mL) and 46 h (1080 [1028 – 
1201] µIU/mL) compared to controls (9.4 [8.7 - 11.5] µIU/mL). Serum IGF-1 concentrations 
did not change significantly, either within or between the control and 46 h groups over the 
infusion period (Table 2). Individual serum IGF-1 concentration is shown for each matched 
pair of control and treated (46 h) horses throughout the infusion period (Fig. 1), illustrating a 
trend towards a decrease in IGF-1 concentrations in the treated animals at the 10 h time-point 
(P = 0.08). 
 
GAPDH was determined to be a more stable house-keeping gene than β2-
microglobulin (mean ± SD CT value: GAPDH 28.4 ± 1.84; β2-microglobulin 24.9 ± 3.29), 
which is consistent with the findings of Zhang et al. (2009) in other equine tissues. Both the 
InsR and IGF-1R genes were expressed in the lamellar tissue of all of the horses (Table 3). 
Gene expression of the InsR was decreased (P < 0.05) in both groups treated with a p-EHC, 
compared with controls. InsR gene expression in the treated groups did not differ from each 
other. Likewise, gene expression of the IGF-1R was decreased (P < 0.05) at both time-points 
in treated horses, compared with controls (Fig. 2). 
Discussion 
To the authors’ knowledge, the current study is the first to examine serum IGF-1 
concentration and lamellar gene expression of the InsR and IGF-1R in horses undergoing a p-
EHC. The results suggest involvement of the IGF system in the pathogenesis of insulin-
induced laminitis and further investigation of the potential for IGF-1R overstimulation as a 
mechanism of the disease is warranted. If activation of the IGF-1R does play a role in the 
pathogenesis of laminitis, it would be useful to know whether this occurs as a result of 
increased IGF-1 production, or whether it is a direct result of hyperinsulinaemia.  
 
Our attempts to measure the local concentration of IGF-1 in the present study using 
qRT-PCR were unsuccessful, but in pigs, it has been suggested that serum IGF-1 levels are a 
useful marker of total IGF-1 production from both the liver and local tissues (Owens et al., 
1997). Together with several earlier studies, the work of Owens et al. (1997) recognised the 
importance of local IGF-1 production in driving processes such as muscle growth (relative to 
that produced by the liver), but demonstrated how plasma IGF-1 levels were a useful, if 
lagging indicator of those processes, and hence of total IGF-1 activity. The serum 
concentrations observed in the present study were well within the normal range for IGF-1, as 
determined by a comprehensive population study involving 1880 horses (Noble et al., 2007). 
 
Although the number of horses used in the present study was small, we sought to 
minimise potential variability due to age, genetics, nutrition, exercise, gender and stress, 
through our experimental design. Furthermore, baseline IGF-1 concentrations were in the 
range 80 - 250 µg/L, whereas horses treated with equine growth hormone are capable of 
producing IGF-1 concentrations of between 600 and 1400 µg/L (Noble and Sillence, 2001a). 
Thus, if the p-EHC procedure had caused a marked inductive effect on IGF-1, we would 
expect to have observed this using the present experimental design. In fact, the horses treated 
with insulin showed a trend towards a transient decrease in serum IGF-1 10 h after the insulin 
infusion commenced. This may indicate a short-term counter-regulatory response to the onset 
of hyperinsulinaemia, but a larger sample size would be required to investigate this trend 
further. Significantly, the lack of an increase in IGF-1 is consistent with the hypothesis that 
IGF-1R downregulation occurred as a result of overstimulation by insulin. 
     
The results of the gene expression work showed that the genes encoding the InsR and 
the IGF-1R are present in equine lamellar tissue, a finding consistent with previous 
immunolocalisation of the IGF-1R in lamellar epidermal epithelial cells and the InsR in 
dermal endothelial and interstitial cells (Bailey and Chockalingham, 2009; Burns et al., 
2011). Interestingly, the InsR has not been identified in lamellar epithelium (Burns et al., 
2011), which supports the hypothesis that lamellar epidermal basal cell proliferation may be 
mediated primarily through the IGF-1R. Both the InsR and IGF-1R genes were down-
regulated during the developmental (24 h) and acute (46 h) stages of insulin-induced 
laminitis, compared to controls.  
 
Once bound, tyrosine kinase receptors undergo endocytosis and are degraded, rather 
than recycled to the plasma membrane, in a process known as receptor down-regulation 
(Komada and Kitamura, 2005). Down-regulation of hormone receptors can occur within 20 h 
and function to limit cellular proliferative activity and prevent excessive cell growth 
(Rosenfeld and Dollar, 1982; Komada and Kitamura, 2005). Furthermore, the overstimulation 
of tyrosine kinase receptors causes a reduction in gene expression so that fewer receptors are 
made (Madan et al., 2011). Downregulation of both the InsR and IGF-1R in the treated horses 
suggests that increased binding and activation of these receptors occurred during the 
development of laminitis, consistent with the study hypothesis.  
 
Activation of the IGF system is known to increase cell survival through a reduction in 
programmed cell death (Pavelic et al., 2007). We have observed that histomorphological 
evidence of apoptosis in lamellar tissue is less evident later in the developmental stages of 
insulin-induced laminitis (de Laat et al., 2012a). In the same study, we observed an increase 
in lamellar basal cell proliferation during the developmental and acute stages of the disease, 
demonstrated by immunolabelling TPX2, a cellular proliferation marker. Thus, engagement 
of the IGF system, leading to inappropriate cell proliferation with lamellar weakening, is a 
possible component of the pathogenesis of insulin-induced laminitis.  
 
Promotion of cell growth following binding and activation of the IGF-1R occurs via 
intracellular cell signalling pathways, including PI3-K and MAP-K (Chitnis et al., 2008). 
These pathways have not been investigated during hyperinsulinaemic laminitis, and they may 
prove to be important in disease pathogenesis. Insulin also activates these pathways following 
binding to its own receptor (Myers and White, 1996), and it is possible that a combined effect 
of insulin and IGF-1 receptor binding, by insulin, occurs during hyperinsulinaemia in horses. 
Thus, further investigation may reveal whether insulin-induced laminitis is a consequence of 
excessive activation of the intracellular signalling pathways mediated by insulin and the IGF 
system. 
 
Furthermore, the theory that the lamellar hyper-proliferation of hyperinsulinaemic 
laminitis is triggered by insulin-activation of the IGF-1R, is supported by an independent in 
vitro study using a primary culture of lamellar epithelial cells (Bailey and Chockalingham, 
2009). This study not only demonstrated that cells incubated with increasing concentrations 
of insulin showed a dose-dependent increase in cell proliferation, but also that the effect of 
insulin was attenuated by the addition of a specific IGF-1R antibody. Interest in the 
therapeutic use of IGF-1R antibodies has existed for over 20 years, since it was discovered 
that IGF-1 promotes tumour progression (Pollak et al., 2001; Majeed et al., 2005; Raina et al., 
2007). Elevated IGF-1 levels in humans are also associated with an increased incidence of 
several types of neoplasia including breast, prostate and colon cancer (Peyrat et al., 1993; Ma 
et al., 1999). Thus, anti-IGF-1R antibodies have been used experimentally and in several 
clinical trials as an adjunct to cancer therapy (Atzori et al., 2009; Olmos et al., 2010). If 
hyperinsulinaemic laminitis is also proven to occur via the IGF-1R pathway, then anti-IGF-1 
antibodies and synthetic receptor blocking agents could be useful in mitigating the 
development of this form of laminitis.  
Conclusions 
By demonstrating a decrease in IGF-1R expression, the current study provides 
indirect, but convincing evidence that IGF-1Rs are over-stimulated during the developmental 
stages of equine laminitis. This likely occurs as a direct result of hyperinsulinaemia, rather 
than an increase in IGF-1 production, as the latter did not occur and the former was 
experimentally induced. Given that decreased cell death and increased cell proliferation are 
known effects of IGF-1R stimulation, engagement of the IGF system, leading to 
inappropriate cell proliferation with lamellar weakening, is a possible mechanism at play in 
the pathogenesis of insulin-induced laminitis. Further research is needed to confirm this 
theory including: the identification and sequencing of equine-specific InsR and IGF-1R 
genes; studies on the expression of insulin and IGF-1 receptors; studies of the intracellular 
signalling pathways activated by insulin; and the use of antibodies and synthetic agents to 
block the activation of IGF-1R.  
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Table 1 
Primer sequences and optimised concentrations (nM) for house-keeping and target genes 
used for quantitative qRT-PCR analysis. 
Gene Forward primer 
(5'-3') 
Reverse primer 
(5'-3') 
Amplic
on size 
(bp) 
Prim
er 
conc. 
(nM) 
β2- 
microglob
ulin 
 
ACCCAGCAGAGAATGGA
AAGC 
 
CATCTTCTCTCCATTCTTTAGC
AAATC 
 
101 
 
600 
GAPDH GAT TGT CAG CAA TGC 
CTC CT 
AAG CAG GGA TGA TGT TCT 
GG 
193 500 
InsR CGAGTTGGATTATTGCCT
CAAAG 
CGTACTCACTCTGATTGTGCT
TCTG 
101 600 
IGF-1R TCCAGACAGGAGTACAGG
AA 
AGAAGAACACGGGATCCGTC
CA 
127 600 
 
Table 2 
Median (range) serum insulin growth factor -1 concentration (μg/L) of horses treated with a 
hyperinsulinaemic clamp (n = 4) or a balanced electrolyte solution (n = 4) over a 46 h 
infusion period. Results did not differ significantly (P > 0.05) between groups. 
 
Group 0 h 10 h 25 h 46 h P-value 
Control 88 (69-127) 119 (69-173) 93.5 (82-150) 151 (102-206) 0.54 
Group 2 158 (116-215) 77.5 (56-91) 108 (95-178) 166 (100-244) 0.08 
 
 
  
Table 3 
Median (range) gene expression of the insulin and insulin growth factor (IGF)-1 receptors 
determined by qRT-PCR in horses treated with insulin for 24 h (n = 4) and 46 h (n = 4), and 
controls treated with a balanced electrolyte solution (n = 4). Relative gene expression for 
target genes was calculated (2∆CT) against the reference gene GAPDH.  
 
Group Insulin receptor IGF-1 receptor 
Control 0.038 (0.02 - 0.1) * 0.016 (0.011 - 0.034) * 
Group 1 (24 h) 0.003 (0.002 - 0.005) 0.0012 (0.0009 - 0.002) 
Group 2 (46 h) 0.003 (0.002 - 0.004) 0.0005 (0.0005 - 0.001) 
 
* denotes if a group differed (P < 0.05) in gene expression to the other groups for each target 
gene using a Kruskal-Wallis ANOVA on ranks. 
  
Figures 
 
 
Fig. 1. Serum insulin growth factor (IGF)-1 concentration (μg/L) was measured in four pairs 
of Standardbred horses treated with: (A) a prolonged, euglycaemic, hyperinsulinaemic clamp 
for approximately 46 h; or (B) a balanced electrolyte solution for 48 h. Symbols correspond 
for each matched pair.  
 
 
Fig. 2. Gene expression of the insulin receptor and insulin growth factor (IGF)-1 receptor in 
lamellar tissue from horses treated with insulin for 24 (█) and approximately 46 (▒) h 
relative to controls. 
